Back to today’s briefing

Story perspectives

Neuralink Raises $650 Million, Starts Human Trials

6/3/2025

30 4

Summary

Story summary

Neuralink successfully raised $650 million in a Series E funding round, led by ARK Invest and Sequoia Capital.
In 2023, the company secured $280 million in Series D funding.
Human trials have begun, with brain chips implanted in five individuals with severe paralysis.
The FDA granted breakthrough device designation to accelerate technology development.
The recent funding values Neuralink at around $9 billion pre-money.

1 of 1

Story summary

Neuralink successfully raised $650 million in a Series E funding round, led by ARK Invest and Sequoia Capital.
In 2023, the company secured $280 million in Series D funding.
Human trials have begun, with brain chips implanted in five individuals with severe paralysis.
The FDA granted breakthrough device designation to accelerate technology development.
The recent funding values Neuralink at around $9 billion pre-money.